Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Novartis Pharmaceuticals |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00757757 |
This study will evaluate the safety and efficacy of MCS110 in patients with prostate cancer and bone metastases
Condition | Intervention | Phase |
---|---|---|
Prostate Cancer Bone Metastases |
Drug: MCS110 |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase I/II Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MCS110 in Patients With Prostate Cancer and Bone Metastases |
Estimated Enrollment: | 100 |
Study Start Date: | September 2008 |
Estimated Primary Completion Date: | September 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: MCS110
Anti-M-CSF antibody
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Contact: Novartis Pharmaceuticals | +1-800-340-6843 |
United States, Nevada | |
NV Cancer Institute | Not yet recruiting |
Las Vegas, Nevada, United States, 89135 | |
Contact: Nicholas Vogelzang, M.D. 702-822-5433 nvogelzang@nvcancer.org | |
Principal Investigator: Nicholas Vogelzang, M.D. | |
United States, Texas | |
CTRC | Recruiting |
San Antonio, Texas, United States, 78229 | |
Contact: John Sarantopoulas, M.D. 210-450-1789 sarantopoulo@uthscsa.edu | |
Principal Investigator: John Sarantopoulas, M.D. |
Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
Responsible Party: | Novartis ( External Affairs ) |
Study ID Numbers: | CMCS110A2101 |
Study First Received: | September 21, 2008 |
Last Updated: | April 1, 2009 |
ClinicalTrials.gov Identifier: | NCT00757757 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Prostate cancer bone metastases anti-M-CSF |
M-CSF antibody M-CSF Prostate Cancer with bone metastases |
Bone Neoplasms Genital Neoplasms, Male Prostatic Diseases Hematologic Diseases Urogenital Neoplasms Genital Diseases, Male Bone Diseases |
Antibodies Musculoskeletal Diseases Neoplasm Metastasis Bone Marrow Diseases Prostatic Neoplasms Immunoglobulins |
Bone Neoplasms Genital Neoplasms, Male Prostatic Diseases Hematologic Diseases Urogenital Neoplasms Genital Diseases, Male Bone Diseases Neoplastic Processes |
Neoplasms Pathologic Processes Neoplasms by Site Musculoskeletal Diseases Neoplasm Metastasis Bone Marrow Diseases Prostatic Neoplasms |